Results 51 to 60 of about 306,427 (235)

Case report: Double-chambered right ventricle diagnosed in a middle-aged female with hypertrophic cardiomyopathy and atrial flutter: A rare case

Frontiers in Cardiovascular Medicine, 2022
Double-chambered right ventricle (DCRV) is a rare congenital heart defect in adults, manifesting with progressive right ventricular outflow tract obstruction.
Junye Ge, Tong Hu, Yan Liu, Qian Wang, Guanqi Fan, Chuanzhen Liu, Jun Zhang, Shiming Chen, Kellina Maduray, Yun Zhang, Tongshuai Chen, Jingquan Zhong, Jingquan Zhong   +12 more
doaj   +1 more source

Double Transeptal Puncture for SAPIEN M3 Transcatheter Mitral Valve Replacement: Initial Experience, Indications, and Technique

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT The SAPIEN M3 system has been recently approved for transcatheter mitral valve replacement (TMVR). The transeptal guide sheath is used to deploy the dock, which is completely released before inserting and deploying the M3 valve using the same femoral access, transeptal puncture (TSP) and guide sheath.
Clara Fernandez‐Cordon, David Hoare, Aayush Singal, Sanjeev Bhattacharyya, Suneil K. Aggarwal, Michael J. Mullen   +5 more
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Mid-ventricular hypertrophic obstructive cardiomyopathy [PDF]

, 2014
Mid-ventricular hypertrophic obstructive cardiomyopathy is a rare variant form (1%) of hypertrophic obstructive cardiomyopathy. In this case, we report a patient referred for elective cardiac catheterization due to angina and dyspnea on moderate exertion,
Pivatto Junior, Fernando, Krepsky, Ana Maria Rocha, Zago, Alexandre do Canto, Mossmann, Márcio   +3 more
core  

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Effects of Alcohol Septal Ablation on Exercise Hemodynamics, Symptoms, and Quality of Life in Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The impact of alcohol septal ablation (ASA) on exercise hemodynamics, symptoms, and quality of life in patients with obstructive hypertrophic cardiomyopathy is poorly described according to contemporary standards.
Anne M. Dybro, Torsten B. Rasmussen, Roni R. Nielsen, Bertil T. Ladefoged, Anders L. D. Pedersen, Christian J. Terkelsen, Mads J. Andersen, Morten K. Jensen, Steen H. Poulsen   +8 more
doaj   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Hypertrophic Obstructive Cardiomyopathy

New England Journal of Medicine, 2004
A 28-year-old man presents with a two-year history of increasing dyspnea on strenuous exertion and is found to have hypertrophic cardiomyopathy, with a septal thickness of 23 mm and a left ventricular outflow gradient of 80 mm Hg. There is no family history of hypertrophic cardiomyopathy or sudden death.
Rick A. Nishimura, David R. Holmes
  +5 more sources

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Identifying Obstructive Hypertrophic Cardiomyopathy from Nonobstructive Hypertrophic Cardiomyopathy: Development and Validation of a Model Based on Electrocardiogram Features

Global Heart, 2023
Background: The clinical presentation and prognosis of hypertrophic cardiomyopathy (HCM) are heterogeneous between nonobstructive HCM (HNCM) and obstructive HCM (HOCM). Electrocardiography (ECG) has been used as a screening tool for HCM.
Lanyan Guo, Zhiling Ma, Weiping Yang, Fuyang Zhang, Hong Shao, Liwen Liu, Chao Gao, Ling Tao   +7 more
doaj   +1 more source